Study of belantamab plus venetoclax for relapsed myeloma
Part of Blood & lymphatic, Cancer, Heart & circulation, Immune system & allergy clinical trials.
This Phase 1/2 trial tests whether combining belantamab mafodotin with venetoclax can treat multiple myeloma that has come back or did not respond (relapsed/refractory). It focuses on a specific myeloma subtype with a t(11;14) genetic marker, aiming to reduce the cancer in people who have already had several treatments.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be 18 years or older.
- Your body strength score (ECOG) must be 0, 1, or 2.
- You must have myeloma that has progressed after at least one prior treatment line.
- Your lab tests must confirm the t(11;14) myeloma subtype.
- You must have blood counts and organ function within set safety limits (kidneys, liver, and bone-marrow blood cells).
- You must not have had venetoclax before, and no other myeloma treatment within 14 days (with a limited corticosteroid exception).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new way of giving a combination of three drugs—belantamab mafodotin, bortezomib, and dexamethasone—for people with multiple myeloma that has come back or stopped responding to earlier treatments. The goal is to see if a different dosing schedule is more effective and safer.
This trial tests a new drug called belantamab mafodotin (a targeted antibody therapy) combined with standard treatments for multiple myeloma that has come back or stopped responding. It looks at three different drug combinations to see which works best for people who have had 1 or 2 prior treatments.
This Phase 2 study tests whether belantamab mafodotin combined with carfilzomib, pomalidomide, and dexamethasone can better treat multiple myeloma that has come back. It may help people who have already tried other myeloma treatments but whose cancer has progressed again.
This study tests the safety and effectiveness of the drug belantamab, alone or with other treatments, for people with multiple myeloma that has come back or stopped responding to previous treatments.
This early-phase study tests how safe and effective belantamab mafodotin is when combined with lenalidomide and dexamethasone, plus a medicine called nirogacestat, in people with newly diagnosed multiple myeloma who cannot have stem cell transplant. It may help shrink the cancer and improve outcomes, while doctors track side effects.
This program provides access to a new drug called belantamab mafodotin, which is being combined with other medicines for people with multiple myeloma who have run out of standard options. The goal is to see if the combination can help control the disease.
Hear when a new Multiple myeloma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.